Results 51 to 60 of about 10,664 (186)

Targeted Anti‐IL‐1 Immunomodulatory Therapy in Pediatric Onset PPP1R13L‐Related Arrhythmogenic Cardiomyopathy

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg, Savannah Coppersmith, Owen Merritt, Amer Heider, Adam Helms, Thomas Michniacki, Jack Luxford, Sarah Josephi‐Taylor, Philip Roberts, Joshua Meisner   +9 more
wiley   +1 more source

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

RMD Open, 2021
Objective To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS ...
Ulrich A Walker, Jasmin B Kuemmerle-Deschner, Jeremy Levy, Eleni Vritzali, Hal M Hoffman, Tom van der Poll, PHILIP N HAWKINS, Hugh H Tilson, Stephanie Noviello   +8 more
doaj   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Experience with canakinumab in a patient with gout and IgA nephropathy

Современная ревматология, 2019
The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Blockage of interleukin-1β with canakinumab in patients with Covid-19

Scientific Reports, 2020
There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19
Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, Federico Cappuzzo   +22 more
doaj   +1 more source

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. [PDF]

, 2018
BACKGROUND: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases ...
Hashkes, PJ, Quartier, Pierre, Lachmann, HJ, Simon, A, De Benedetti, Fabrizio, Jordi Anton, De Benedetti, F, Hal M. Hoffman, Constantin, Tamas, Tamas Constantin, Eldad, Ben-Chetrit, Brogan, P., Ozen, S., Cattalini, M, Constantin, T, Ozen, S, Koné-Paut, I, Gul, A., Obici, L., Hoffman, HM, Hara, R., Ozgur Kasapcopur, Ahmet Gul, Anna Simon, Frenkel, Joost, Lachmann, Helen J., Speziale, Antonio, PENADES, I. Calvo, Frenkel, J., Calvo Penades, I., Frenkel, J, Hofer, M, Junge, G., Benedetti, F. De, Speziale, A., Quartier, P, Speziale, A, Lheritier, K, Lachmann, H. J., Livneh, A., Simon, A., Zeft, A, Inmaculada Calvo Penades, Junge, Guido, Moutschen, M, Hofer, M., Livneh, Avi, Gattorno, M, Isabelle, Koné-Paut, Fabrizio De Benedetti, Calvo Penades, I, Paul Brogan, Van der Hilst, Jeroen, Bujan-Rivas, S, Simon, Anna, ZEFT, A., Penades, Inmaculada Calvo, Avi Livneh, Hofer, Michael, Moutschen, M., Eldad Ben-Chetrit, Michel Moutschen, Hashkes, Philip J., Ryoki Hara, Hoffman, H.M., Shcherbina, A., KONE-PAUT, I., Obici, L, Kone-Paut, Isabelle, Andrew Zeft, Lachmann, H.J., Hoffman, Hofman M., Segundo Bujan-Rivas, Guido Junge, Joost Frenkel, Anton, J., Shcherbina, Anna, Isabelle Koné-Paut, Ozen, Seza, Michael Hofer, Kasapcopur, Ozgur, Segundo, Bujan Rivas, Shcherbina, A, Hara, Ryoki, Ben-Chetrit, Eldad, Marco Gattorno, Gattorno, M., Kasapcopur, O, Quartier, P., Kasapcopur, O., Gul, A, Obici, Laura, Laura Obici, Moutschen, Michel, Constantin, T., Antonio Speziale, Ben-Chetrit, E, Seza Ozen, Hashkes, P.J., Ben-Chetrit, E., Van der Hilst, J, Lheritier, Karine, Philip J. Hashkes, Bujan-Rivas, Segundo, Brogan, P, Hoffman, Hal M., Zeft, Andrew, Cattalini, Marco, Jeroen Van der Hilst, Anton, Jordi, Marco Cattalini, Eldad, Ben Chetrit, Brogan, Paul, Bujan-Rivas, S., Hashkes, P. J., Gattorno, Marco, Segundo, Bujan-Rivas, Anna Shcherbina, Calvo Penades, Inmaculada, Karine Lheritier, HOFFMAN, H. M., Lheritier, K., Van der Hilst, J., Anton, J, Livneh, A, Junge, G, Pierre Quartier, Hara, R, Helen J. Lachmann, DE BENEDETTI, F., Gul, Ahmet, Isabelle, Koné Paut, Cattalini, M.   +132 more
core   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

Global & Regional Health Technology Assessment, 2020
Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and ...
Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi   +2 more
doaj   +1 more source

Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab

, 2020
Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin ...
Conte, Mariasole, Tommasini, Alberto, Pastore, Serena, Taddio, Andrea, Berti, Irene   +4 more
core